Trial reportAmerican journal of clinical dermatology2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Trial report in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01949311 (An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials), which is not on this map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Efficacy and Safety of IL-4Rα Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials.The Australasian journal of dermatology · 2026Pooled it
- European Guideline (EuroGuiDerm) on atopic eczema: Living update.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review.Biomolecules · 2023Pooled it
- Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.Advances in therapy · 2026Trial
- The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.American journal of clinical dermatology · 2025Trial
- Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.Frontiers in immunology · 2024Trial
- Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.The British journal of dermatology · 2023Trial
- The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.The British journal of dermatology · 2022Trial
- Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.Allergy · 2022Trial
- Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.International forum of allergy & rhinology · 2021Trial
- Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.The British journal of dermatology · 2021Trial
- Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study.Dermatology and therapy · 2026Article
- Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.Postepy dermatologii i alergologii · 2026Article
- Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria.Dermatology research and practice · 2026Review
- From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.International journal of molecular sciences · 2025Review
- Emerging concepts in atopic dermatitis and atopic keratoconjunctivitis.Current opinion in allergy and clinical immunology · 2025Review
- An Overview of Atopic Dermatitis Disease Burden, Pathogenesis, and the Current Treatment Landscape: Recommendations for Appropriate Utilization of Systemic Therapies.The Journal of clinical and aesthetic dermatology · 2025Review
- Infections in Patients with Atopic Dermatitis and the Influence of Treatment.American journal of clinical dermatology · 2025Review
- Clinical curative effect and quality of life evaluation of dupilumab in treating children with atopic dermatitis and its effect on IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine.Postepy dermatologii i alergologii · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment.
objectiveThe aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD.
methodsThis ongoing, multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) assessed dupilumab treatment in adults previously enrolled in dupilumab trials. Patients received dupilumab 300 mg weekly up to 148 weeks. The primary outcome was safety.
resultsOf 2677 patients enrolled and treated, 347 reached week 148. Mean self-reported drug compliance was 98.2%. Safety data were consistent with previously reported trials (270.1 adverse events [AEs]/100 patient-years; 6.9 serious AEs/100 patient-years) and the known dupilumab safety profile. Common AEs (≥ 5% of patients) included nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions. AD signs and symptoms showed sustained improvements during treatment with mean (standard deviation, mean percentage change from parent study baseline) Eczema Area and Severity Index 1.4 (3.2, - 95.4%) and weekly Pruritus Numerical Rating Scale 2.2 (1.8, - 65.4%) at week 148. LIMITATIONS: No control arm; fewer patients at later time points; regimen different from the approved 300 mg every 2 weeks dose.
conclusionThese safety and efficacy results support dupilumab as a continuous long-term treatment for adults with moderate-to-severe AD.
trial registrationClinicalTrials.gov: NCT01949311. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis (MP4 139831 kb).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.